In early 2001 there was a dramatic decline in the availability of heroin in New South Wales (NSW), Australia, where previously heroin had been readily available at a low price and high purity. 1 The decline was confirmed by Australia's strategic early warning system, which revealed a reduction in heroin supply across Australia and a considerable increase in price, 2 particularly from January to April 2001.
This "heroin shortage" provided a natural experiment in which to examine the effect of substantial changes in price and availability on injecting drug use and its associated harms in Australia's largest heroin market, 2 a setting in which harm reduction strategies were widely used. Publicly funded needle and syringe programmes were introduced to Australia in 1987, and methadone maintenance programmes, which were established in the 1970s, were significantly expanded in 1985 and again in 1999.
Methods and results
In NSW needle and syringe programmes are delivered primarily within the public sector through area health services. There is also a private sector programme, subsidised by the government, delivered through pharmacies (known as "fitpacks"). This enables injecting drug users to purchase or exchange needles and syringes. We used data collected by these programmes to examine the extent of injecting drug use. These data are representative of all needles and syringes distributed to injecting drug users in NSW and have been combined to produce quarterly comparable data.
The number of needles and syringes distributed in NSW decreased around the onset of the heroin shortage (figure) and the reduction was sustained until the end of the period for which data were available. The number of needles distributed decreased from around 3.1 million per quarter immediately before the heroin shortage to just under 2.2 million in mid-2002-a decrease of around 28%. Time series analysis on monthly data from major needle and syringe programmes suggested that this decline was not a seasonal effect and was tied closely to the onset of the shortage (analysis available on request).
Comment
We found a sustained reduction in the number of needles and syringes distributed in NSW after a considerable decrease in heroin supply. Given the widespread and easy availability of needles and syringes in NSW, the data on provision are a useful proxy for changes in the number of injecting drug users or in the frequency of injecting, or both. The trends observed here were also consistent with estimated reductions in the number of regular heroin users after the heroin shortage. 3 These data suggest an overall reduction in the prevalence of injecting drug use after a decrease in heroin supply.
We relied on secondary data sources as indirect measures of the prevalence of injecting drug use. None the less, the coherent pattern of changes outlined in this study is not easily explained by any other hypotheses and is consistent with other research on the consequences of the heroin shortage. in heroin supply. 4 Nearly all such infections are related to injecting drug use, and there are no alternative explanations for the decrease in notifications, which was not predicted by mathematical models of the hepatitis C epidemic in Australia. 5 However, the true impact of reduced supply is unlikely to be detectable for some time. Reduction in injecting drug use, as indicated by reduced output in the needle and syringe programmes, would be consistent with reduction in such infections at the population level. We are currently exploring further impacts of the shortage on overdose, treatment, and crime.
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Contributors: CD (guarantor), LD, and WH conceived the study. LD supervised the research. CD led the writing. SG conducted the analysis for the study. All authors helped to conceptualise ideas, interpret findings, and review drafts of the manuscript. Thiazolidinediones are peroxisomal proliferator activated receptor agonists. Troglitazone is associated with idiosyncratic hepatic reaction, liver failure, and death and is withdrawn. 1 2 The toxicity of troglitazone is unlikely to be a class effect of thiazolidinediones since rosiglitazone and pioglitazone have shown little evidence of hepatic toxicity.
3 Some patients taking pioglitazone, however, have had liver failure, but no deaths are associated with it. 4 A 63 year old white man with no history of alcohol misuse was admitted to hospital with jaundice after feeling unwell for three weeks. Three months before, doctors changed his gliclazide to pioglitazone. He had also taken lercanidipine for some years and a cephalosporin antibiotic for a few days. Blood investigations found concentrations of 522 mol/l bilirubin, 472 IU/l alkaline phosphatase, 1053 IU/l aspartate aminotransferase, 1984 IU/l alanine aminotransferase, 455 mol/l creatinine, and 28 g/l albumin. His prothrombin time was 56 seconds. He developed encephalopathy and acidosis 36 hours after admission and doctors transferred him to intensive care.
He had no stigmata of chronic liver disease, and hepatitis surface antigen, hepatitis A IgM, and hepatitis C antibody were negative. Ultrasound images showed normal parenchymal reflectivity with patent vessels and no biliary dilatation. When stabilised, doctors transferred him to the regional liver unit. He died nine days later.
The histopathology report describes parenchymal damage with steatohepatitis including Mallory bodies superimposed on a severely fibrotic liver. The cause is not certain, but the degree of fibrosis suggests a chronic process, and the type of necroinflammatory activity raises the possibility of alcohol related liver injury. Alternatively the changes could be drug induced damage superimposed on chronic liver disease related to diabetes, and the time scale indicates that pioglitazone is the likely cause.
We know of no previous cases of death associated with pioglitazone, although liver failure has been reported.
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